GE HealthCare Technologies Inc. (GEHC) fair value analysis
S&P 500 & Nasdaq · Updated 2026-10-19
GEHC price how computed
Forward Fair Value verdict
UndervaluedGEHC is trading at more than a 25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $65.74
- Sector
- Healthcare
- 12-month range
- $59.48–$88.16
- Market cap
- $29.7B
- From 52-week high
- -25.4%
- Shares outstanding
- 452M
- Rank in Healthcare by discount to fair value
- #21 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
GE HealthCare Technologies Inc. is a healthcare technology company that designs, manufactures, and sells medical imaging equipment, software, and services including ultrasound, computed tomography, magnetic resonance imaging, and X-ray systems, along with digital healthcare solutions. The company operates globally across multiple regions including North America, Europe, Asia Pacific, and other international markets, serving hospitals, diagnostic imaging centers, and healthcare providers worldwide.
GEHC currently ranks #21 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $29.7B
- P/E (trailing)
- 14x
- Revenue (TTM)
- $20.2B
- Net margin
- 7.9%
- EPS (TTM)
- $4.63
- Gross margin
- 41.2%
- Debt / equity
- 0.92
- Revenue growth (3-yr avg)
- 3.3%
- Shares outstanding
- 452M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Expanding
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 67 · neutral
- 50-day average
- $68.59
- 200-day average
- $70.47
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Dividends how computed
- Paid, last 12 months
- $0.15 per share (4 payments)
- Yield on last price
- 0.22%
- Consecutive years of increases
- 2
- Last ex-dividend date
- 2026-10-23
- Last payment date
- 2026-11-13
Earnings how computed
- Next earnings report
- 2026-10-28 (pre-market)
- Last 8 quarters vs consensus
- 7 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+8.7%)
2026-03 ▼ miss (-5.7%)
2025-12 ▲ beat (+2.9%)
2025-09 ▲ beat (+1.9%)
2025-06 ▲ beat (+15.2%)
2025-03 ▲ beat (+11.0%)
2024-12 ▲ beat (+24.6%)
2024-09 ▲ beat (+8.6%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 15 buy · 5 hold · 0 sell (20 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $82.7
- Target vs last price
- +25.8%
What our data shows for GEHC
- Our model validated 14 trailing price-to-earnings windows for GEHC, built from quarterly earnings records.
- Shares are trading in the lower third of their 12-month price range of $59.48–$88.16.
- The 14-day relative strength index sits at a neutral 67.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for GEHC
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the GEHC conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — GEHC's relative strength index moved from oversold territory into neutral zone this week, indicating a shift in momentum dynamics for the healthcare company. The stock remains classified as undervalued according to TickrTrends' derived valuation assessment. This combination of improving momentum and below-market pricing suggests reduced near-term selling pressure.
- 2026-09-21 — # GEHC Weekly Indicator Summary TickrTrends' derived indicators for GEHC showed a shift this week as the momentum indicator moved from a B rating to none. The stock maintains an undervalued valuation verdict within the Healthcare sector. This change suggests a reduction in the momentum signal strength compared to the prior week's assessment.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is GEHC stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), GEHC is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is GEHC's TickrTrends verdict?
GEHC's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does GEHC compare to other Healthcare stocks?
GEHC ranks #21 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is GEHC overbought or oversold?
GEHC's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does GEHC pay a dividend?
Yes. GEHC paid $0.15 per share over the last twelve months (4 payments), a 0.22% yield on TickrTrends' last price, and has raised the annual total for 2 consecutive years. The last ex-dividend date was 2026-10-23.
When does GEHC report earnings next?
GEHC's next earnings report is scheduled for 2026-10-28 (pre-market), per the published earnings calendar.
Does GEHC usually beat earnings estimates?
Over its last 8 reported quarters GEHC beat the consensus estimate 7 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about GEHC?
Of 20 analysts covering GEHC, 15 rate it a buy, 5 a hold and 0 a sell - buy-leaning, with a consensus price target of $82.7 (+25.8% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
GEHC vs ABCL · GEHC vs ABT · GEHC vs IDXX · GEHC vs INCY · GEHC vs INDV